Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free NIOX Stock Alerts

NIOX Group (NIOX) Competitors

NIOX Group logo
GBX 68.60 -0.20 (-0.29%)
As of 08/21/2026 11:55 AM Eastern
Compare

NIOX vs. AMS, TSTL, EKF, SPEC, and CREO

Should you buy NIOX Group stock or one of its competitors? NIOX Group's main competitors and comparable companies include Advanced Medical Solutions Group (AMS), Tristel (TSTL), EKF Diagnostics (EKF), INSPECS Group (SPEC), and Creo Medical Group (CREO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does NIOX Group compare to Advanced Medical Solutions Group?

Advanced Medical Solutions Group (LON:AMS) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

In the previous week, Advanced Medical Solutions Group's average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company Overall Sentiment
Advanced Medical Solutions Group Neutral
NIOX Group Neutral

NIOX Group has lower revenue, but higher earnings than Advanced Medical Solutions Group. NIOX Group is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced Medical Solutions Group£228.94M2.68£11.22M£4.5262.28
NIOX Group£48.70M5.93£995.88M£1.6441.83

22.7% of Advanced Medical Solutions Group shares are owned by institutional investors. Comparatively, 7.6% of NIOX Group shares are owned by institutional investors. 4.0% of Advanced Medical Solutions Group shares are owned by company insiders. Comparatively, 5.1% of NIOX Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NIOX Group has a net margin of 14.37% compared to Advanced Medical Solutions Group's net margin of 4.35%. NIOX Group's return on equity of 10.14% beat Advanced Medical Solutions Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced Medical Solutions Group4.35% 3.87% 2.35%
NIOX Group 14.37%10.14%3.95%

Advanced Medical Solutions Group has a beta of 0.704, meaning that its share price is 30% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Advanced Medical Solutions Group currently has a consensus target price of GBX 270.25, suggesting a potential downside of 4.00%. NIOX Group has a consensus target price of GBX 86, suggesting a potential upside of 25.36%. Given NIOX Group's stronger consensus rating and higher probable upside, analysts clearly believe NIOX Group is more favorable than Advanced Medical Solutions Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Medical Solutions Group
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.0%. NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 1.8%. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

NIOX Group beats Advanced Medical Solutions Group on 10 of the 16 factors compared between the two stocks.

How does NIOX Group compare to Tristel?

Tristel (LON:TSTL) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

NIOX Group has lower revenue, but higher earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M4.15£6.54M£16.2426.39
NIOX Group£48.70M5.93£995.88M£1.6441.83

Tristel has a beta of 0.346, meaning that its share price is 65% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

22.5% of Tristel shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Comparatively, 5.1% of NIOX Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tristel's average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company Overall Sentiment
Tristel Neutral
NIOX Group Neutral

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.3%. NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 1.8%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Tristel has a net margin of 15.88% compared to NIOX Group's net margin of 14.37%. Tristel's return on equity of 23.64% beat NIOX Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
NIOX Group 14.37%10.14%3.95%

NIOX Group has a consensus price target of GBX 86, suggesting a potential upside of 25.36%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts plainly believe NIOX Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Tristel and NIOX Group tied by winning 8 of the 16 factors compared between the two stocks.

How does NIOX Group compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

NIOX Group has lower revenue, but higher earnings than EKF Diagnostics. NIOX Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.12£4.68M£0.4754.04
NIOX Group£48.70M5.93£995.88M£1.6441.83

EKF Diagnostics presently has a consensus target price of GBX 35, indicating a potential upside of 37.80%. NIOX Group has a consensus target price of GBX 86, indicating a potential upside of 25.36%. Given EKF Diagnostics' higher possible upside, equities analysts clearly believe EKF Diagnostics is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

NIOX Group has a net margin of 14.37% compared to EKF Diagnostics' net margin of 4.12%. NIOX Group's return on equity of 10.14% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
NIOX Group 14.37%10.14%3.95%

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 40.0% of EKF Diagnostics shares are held by company insiders. Comparatively, 5.1% of NIOX Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

EKF Diagnostics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

In the previous week, EKF Diagnostics had 2 more articles in the media than NIOX Group. MarketBeat recorded 2 mentions for EKF Diagnostics and 0 mentions for NIOX Group. EKF Diagnostics' average media sentiment score of 0.34 beat NIOX Group's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
EKF Diagnostics Neutral
NIOX Group Neutral

Summary

EKF Diagnostics beats NIOX Group on 8 of the 14 factors compared between the two stocks.

How does NIOX Group compare to INSPECS Group?

INSPECS Group (LON:SPEC) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

NIOX Group has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A
NIOX Group£48.70M5.93£995.88M£1.6441.83

INSPECS Group presently has a consensus target price of GBX 60, suggesting a potential downside of 34.78%. NIOX Group has a consensus target price of GBX 86, suggesting a potential upside of 25.36%. Given NIOX Group's higher possible upside, analysts clearly believe NIOX Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
NIOX Group Neutral

0.7% of INSPECS Group shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 19.6% of INSPECS Group shares are held by company insiders. Comparatively, 5.1% of NIOX Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

INSPECS Group has a beta of 1.607, suggesting that its share price is 61% more volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

NIOX Group has a net margin of 14.37% compared to INSPECS Group's net margin of -2.67%. NIOX Group's return on equity of 10.14% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
NIOX Group 14.37%10.14%3.95%

Summary

NIOX Group beats INSPECS Group on 9 of the 12 factors compared between the two stocks.

How does NIOX Group compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Creo Medical Group currently has a consensus price target of GBX 40, suggesting a potential upside of 207.69%. NIOX Group has a consensus price target of GBX 86, suggesting a potential upside of 25.36%. Given Creo Medical Group's higher probable upside, research analysts plainly believe Creo Medical Group is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

NIOX Group has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.53-£25.04M£1.0013.00
NIOX Group£48.70M5.93£995.88M£1.6441.83

Creo Medical Group has a net margin of 88.33% compared to NIOX Group's net margin of 14.37%. NIOX Group's return on equity of 10.14% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
NIOX Group 14.37%10.14%3.95%

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 7.0% of Creo Medical Group shares are held by insiders. Comparatively, 5.1% of NIOX Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Creo Medical Group had 1 more articles in the media than NIOX Group. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for NIOX Group. Creo Medical Group's average media sentiment score of 0.75 beat NIOX Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media.

Company Overall Sentiment
Creo Medical Group Positive
NIOX Group Neutral

Creo Medical Group has a beta of 1.563854, suggesting that its share price is 56% more volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Summary

Creo Medical Group and NIOX Group tied by winning 8 of the 16 factors compared between the two stocks.

Get NIOX Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for NIOX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NIOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NIOX vs. The Competition

Export
MetricNIOX GroupHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£288.71M£6.02B£7.37B£2.54B
Dividend Yield2.26%1.74%2.53%6.17%
P/E Ratio41.8326.67272.60367.57
Price / Sales5.9371.61624.3383,481.74
Price / Cash11.2133.2478.6227.89
Price / Book3.806.2313.057.19
Net Income£995.88M£150.07M£3.47B£5.89B
7 Day Performance5.80%0.69%2.09%0.30%
1 Month Performance8.89%8.91%6.64%3.31%
1 Year Performance-1.44%8.07%25.02%22.13%

NIOX Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NIOX
NIOX Group
2.5572 of 5 stars		GBX 68.60
-0.3%		GBX 86
+25.4%		-1.4%£288.71M£48.70M41.8392
AMS
Advanced Medical Solutions Group
1.1004 of 5 stars		GBX 280.50
-0.4%		GBX 270.25
-3.7%		+35.3%£610.36M£228.94M62.0610
TSTL
Tristel
N/AGBX 420
+2.4%		N/A+17.4%£201.59M£49.54M25.86208
EKF
EKF Diagnostics
2.6664 of 5 stars		GBX 25.30
flat		GBX 35
+38.3%		-7.3%£108.78M£51.56M53.83356
SPEC
INSPECS Group
0.5898 of 5 stars		GBX 94
-3.1%		GBX 60
-36.2%		+111.3%£102.62M£191.70MN/A1,673

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NIOX) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Earth's biggest energy source: near Grand Canyon
The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...
Behind the Markets | Sponsoredtc pixel